CHOOLIP & SCIENCES Inc. (KOSDAQ:291650)

South Korea · Delayed Price · Currency is KRW

2,385.00

-85.00 (-3.44%)

At close: Nov 6, 2026

Market Cap	72.79B +179.3%
Revenue (ttm)	n/a +281.6%
Net Income	n/a
EPS	n/a
Shares Out	30.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,087
Open	2,305.00
Previous Close	2,470.00
Day's Range	2,305.00 - 2,485.00
52-Week Range	1,507.00 - 9,990.00
Beta	-0.36
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CHOOLIP & SCIENCES

CHOOLIP & SCIENCES Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. The company was formerly known as Aptamer Sciences Inc and changed its name to CHOOLIP ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2011

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 291650

Full Company Profile

Financial Performance

In 2024, Aptamer Sciences's revenue was 1.08 billion, an increase of 345.26% compared to the previous year's 243.19 million. Losses were -8.70 billion, -36.02% less than in 2023.

Financial Statements